Evidence suggests that the deregulation of SRC Family Kinases may play a role in the 37 development of heritable pulmonary arterial hypertension, associated with BMPR2 38 mutations. The truncated c-terminus of the BMPR2 protein is known to increase the 39 phosphorylation and downstream activity of SRC tyrosine kinases. To test the hypothesis 40 that the inhibition of SRC can prevent heritable PAH due to a BMPR2 mutation, we 41 exposed BMPR2 mutant mice to SRC inhibitors, saracatinib and dasatinib, to block the 42 SRC activation caused by the BMPR2 mutation. Saracatinib and dasatinib failed to 43 prevent the development of PAH in BMPR2 mutant mice. Increased pressure in the right 44 ventricle was not normalized and muscularization of large blood vessels was not reduced 45 when compared to wild type mice. Inhibiting SRC's phosphorylation does not prevent 46 heritable PAH, and thus supports evidence that SRC's aberrant localization and 47 128 sectioned after the mice were treated for four weeks with saracatinib, dasatinib, or 129 vehicle. 130 Lung sections were stained with α smooth muscle actin (αSMA, Sigma) and 131 DAPI. To quantify αSMA positive vessels, an observer blinded to treatment group 132 counted the numbers of fully muscularized vessels per field in 10 random 10x fields in 133 three mice per group. αSMA positive vessels were stratified by diameter (<25um or 50-134 100um). Vessels were identified with a Nikon Eclipse Ti microscope and were measured 135 along the longest axis. The apexes and edges of the lungs were avoided in histological 136 quantification and observation.
Pulmonary arterial hypertension (PAH) is a progressive and fatal illness of the 64 pulmonary microvasculature. The remodeling of the small resistance arteries in the lung 65 leads to increased pulmonary vascular resistance, increasing the workload on the heart's 66 right ventricle (RV) until it eventually fails (1, 2) .
68
The most studied heritable risk factor for the development of PAH is a mutation 69 in the type 2 receptor in the BMP pathway (BMPR2). However, the mechanism 70 underlying BMPR2 and the development of PAH is not well understood (3) (4) (5) (6) surgical anesthesia (Avertin) and the RVSP was measured by inserting a catheter into the 116 right heart through the right jugular vein in a closed-chested procedure, as previously 117 described (17). Ten-second segments of RVSP measurement were extracted from the 118 RVSP waveform, and the maximum RVSP was calculated by measuring the difference 119 between the peak and trough of the wave.
120
After sacrifice, tissues were collected for further analysis. All surgical procedures 121 were approved by the Vanderbilt institutional animal care and use committee (IACUC).
122

Histology & Western Blots
123
After RVSP measurement, the lungs were flushed with 5 mL phosphate buffer 124 solution (PBS) via perfusion through the right ventricle. To remove the blood, a small cut 125 was placed in the left atrium. The lungs were then inflated with 0.8% low melt agarose.
126
The lungs from mice with or without an activated R899X mutation in the BMPR2 127 receptor were isolated, embedded with Optimal Cutting Temperature compound, and associated with multiple molecular abnormalities including increased SRC phosphorylation.
156
To determine whether inhibition of this SRC activity would prevent pulmonary 157
hypertension, age and sex matched wild type and ROSA26-BMPR2 R899X mutant mice were 158 treated with saracatinib and dasatinib for the last four weeks during six weeks of transgene 159
activation. Saracatinib and dasatinib were shown to inhibit the action of downstream targets in the 160 SRC pathways (Figure 1) , indicating proper osmotic delivery through the subcutaneously placed 161 pumps to achieve direct SRC inhibition.
162
While vehicle-treated mice developed elevated RVSP at about 35% penetrance, mice 163 treated with SRC inhibitors have pressures indistinguishable from the vehicle-treated BMPR2 164 mutants (Figure 2) . BMPR2 mutant mice have greater RVSPs than WT mice (p<0.05) and 165 delivery of saracatinib and dasatinib to mutant mice does not reduce RVSP when compared 166 vehicle treated mutants (p>0.05).
167
Lung sections from ROSA26-BMPR2 R899X mutant mice had an increased number of 168 large muscularized vessels when compared to the WT mice (p<0.05) (Figure 3) . The number of 169 large muscularized vessels in the mutant mice was not reduced to the wild type mice by 170 saracatinib and dasatinib treatment (p>0.05). The number of fully muscularized vessels is about 171 doubled in all BMPR2 mutant mice, independent of treatment. All vessels were consistently 172 measured along the longest axis and included the border of the masculinized vessels. Fully 173 muscularized vessels were measured and vessels that did not have at least 75% vessel perimeter 174
were excluded from the analysis. The muscles were stratified within Nikon and analyzed within 175 R. All imaging channels were taken manually and overlaid in ImageJ. These results suggest that saracatinib and dasatinib do not prevent the onset of PAH 181 despite inhibiting the downstream activity of phosphorylated SRC due to the BMPR2 mutation 182 (Figure 1) . Wild type BMPR2's cytoplasmic tail binds with SRC but does not lead to its abnormal 183 phosphorylation. The truncated cytoplasmic tail in the mutant BMPR2 protein results in both the 184 increase in phosphorylation and downstream activity of SRC. The administration of saracatinib 185
and dasatinib are known to inhibit SRC's activity (15 , 16) . Previous studies have shown that 186
antagonizing other proteins in the SRC pathways have resulted in the amelioration of PAH in 187 identical animal models (14). Here, we show that inhibiting this downstream activity by other 188 therapeutic agents does not prevent the development of PAH.
189
Western blots confirm that both saracatinib and dasatinib inhibit as expected, with 190 decreased expression of a key protein downstream of SRC. The animal model also revealed an 191 expected penetrance and development of PAH, as measured through RVSP (Figure 2) . Despite 192 therapeutic intervention, the elevated RVSP in the Rosa26-Bmpr2 R899X mutant mice was not 193
lowered. This finding suggests that the inhibition of SRC and its downstream activity do not 194
reduce the elevated pressures that are hallmark of PAH.
195
Rosa26-Bmpr2 R899X mice had about twice the amount of large fully muscularized vessels 196 when compared to the wild type mice. The administration of saracatinib and dasatinib failed to 197 normalize the number of vessels. This finding once again suggests that saracatinib and dasatinib 198
do not prohibit the development of heritable PAH.
199
Because previous success was seen by antagonizing the SRC pathway in PAH, further 200 efforts should focus on understanding the complexity of the interaction between SRC and the 201 truncated cytoplasmic tail in the BMPR2 mutation in PAH. It is plausible that the development of 202 PAH may not be due to the phosphorylation or downstream activity associated with SRC's 203 differential regulation. Other studies have shown that SRC trafficking and localization is altered 204 within the mutant cells when compared to the wild type cells (14). A previous study interrogated 205 the SRC pathway in heritable PAH and found success in preventing the onset of disease (14). 206
However, a key difference is that this previous study also aimed to restrict the aberrant SRC 207 trafficking seen in mutant cells. Therefore, it is possible that the differential trafficking of SRC in 208 heritable PAH plays a significant role in disease development and the inhibition of SRC itself is 209 only part of the strategy that would need to be adopted the treat the disease. SRC is known to 210 be sequestered in its phosphorylated form in PAH, and is thus unable to activate distant targets. 211
This sequestration may be the dominating problem in SRC's role in PAH, and inhibiting SRC's 212 phosphorylation may be the incorrect target to prevent heritable PAH (14). Interestingly, one of 213 the therapies, dasatinib, is known to cause PAH in humans (19). This clinical observation further 214
bolsters our belief that inhibiting SRC does not prevent disease, and the localization and 215
trafficking is a more likely player in pathogenesis. Our study indicates that more information is Western blots from ROSA26-BMPR2 R899X mutant lung treated with saracatinib, dasatinib, or vehicle. Mutants have increased phosphorylation of SRC target, CAS. CAS phosphorylation and activity is reduced with saracatinib and dasatinib treatment. Figure 3: Saracatinib and Dasatinib do not normalize large muscularized vessels in mutant mice. A) ROSA26-BMPR2 R899X mutants and wilt type mice have about the same number of small muscularized vessels per field. However, ROSA26-BMPR2 R899X mutants have about twice as many fully muscularized large sized vessels (50-100um). Saracatinib and dasatinib administration did not normalize the number of large muscularized vessels in the mutant mice. The error bars are reported as SEM. B) Representative images of the ROSA26-BMPR2 R899X mutants and wild type mice illustrate indistinguishable changes in muscularized vessels after administration of saracatinib and dasatinib. Images are taken at 10x.
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